Discover
VYGR
Voyager Therapeutics, Inc.
3.60
2 x 2.52
2 x 4.46
bid
ask
+
0.10
2.86%
2 @ 05:38 AM
3.51 -0.09 (2.50%)
| Ytd | -8.40% | |
| 1y | 12.50% |
3.44
day range
3.61
2.88
52 week range
5.55
| Open | 3.50 | Prev Close | 3.50 | Low | 3.44 | High | 3.61 | Mkt Cap | 217.52M |
| Vol | 538.66K | Avg Vol | 570.66K | EPS | -1.98 | P/E | N/A | Forward P/E | -3.41 |
| Beta | 0.89 | Short Ratio | 4.44 | Inst. Own | 65.52% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 3.74 | 200-d Avg | 4.07 | 1yr Est | 17.10 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -0.45 | -0.16 | 0.29 | 64.44% |
| 2024-08-06 | 2024-06 | -0.38 | -0.18 | 0.2 | 52.63% |
| 2024-05-13 | 2024-03 | -0.44 | -0.2 | 0.24 | 54.55% |
| 2024-02-28 | 2023-12 | -0.59 | 1.25 | 1.84 | 311.86% |
| 2023-11-06 | 2023-09 | -0.58 | -0.59 | -0.01 | -1.72% |
| 2023-08-03 | 2023-06 | -0.59 | -0.51 | 0.08 | 13.56% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-02 | Citigroup | Upgrade | Buy | |
| 2024-11-14 | Canaccord Genuity | Upgrade | Buy | Buy |
| 2024-11-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-24 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-16 | Leerink Partners | Upgrade | Outperform | |
| 2024-08-20 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-02-20 | CARTER TODD ALFRED | Officer | 87.63K | Sale |
| 2024-10-01 | FAHEY SANDELL JACQUELYN | Officer | 86.00K | Sale |
| 2024-03-31 | FERGUSON TOBY | Officer | 105.00K | Stock Award(Grant) |
| 2023-03-19 | HESSLEIN ROBERT W | General Counsel | 102.20K | Sale |
| 2024-09-30 | JORGENSEN NATHAN D. | Chief Financial Officer | 80.00K | Stock Award(Grant) |
| 2023-02-22 | NEUROCRINE BIOSCIENCE INC | Beneficial Owner of more than 10% of a Class of Security | 8.58M | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Blackrock Inc. | 5.43M | 31.12M | 9.94% |
| 2024-09-29 | Armistice Capital, LLC | 5.20M | 29.80M | 9.52% |
| 2024-09-29 | EcoR1 Capital, LLC | 3.92M | 22.45M | 7.17% |
| 2024-09-29 | Vanguard Group Inc | 3.19M | 18.26M | 5.83% |
| 2024-09-29 | Farallon Capital Management LLC | 2.29M | 13.13M | 4.20% |
| 2024-09-29 | Dimensional Fund Advisors LP | 1.11M | 6.33M | 2.02% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 1.71M | 9.82M | 3.14% |
| 2024-10-30 | iShares Russell 2000 ETF | 1.21M | 6.91M | 2.21% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 646.40K | 3.70M | 1.18% |
| 2024-09-29 | Price (T.Rowe) Health Sciences Fund | 622.40K | 3.57M | 1.14% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 469.64K | 2.69M | 0.86% |
| 2024-07-30 | Vanguard Explorer Fund, Inc. | 457.06K | 2.62M | 0.84% |